Oxbow Advisors LLC Invests $4.88 Million in Medpace Holdings, Inc. $MEDP

Oxbow Advisors LLC acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, HoldingsChannel.com reports. The fund acquired 9,208 shares of the company’s stock, valued at approximately $4,876,000.

Several other institutional investors have also added to or reduced their stakes in MEDP. California State Teachers Retirement System raised its holdings in Medpace by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of Medpace by 41.0% in the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after purchasing an additional 23,530 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new stake in shares of Medpace in the 2nd quarter valued at $1,685,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Medpace by 24,930.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after buying an additional 100,968 shares during the period. Finally, Mitchell Capital Management Co. acquired a new stake in shares of Medpace during the fourth quarter worth $3,383,000. 77.98% of the stock is currently owned by institutional investors.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 17,610 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total value of $10,655,987.10. Following the completion of the sale, the chief executive officer directly owned 615,802 shares of the company’s stock, valued at $372,627,948.22. This trade represents a 2.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 67,195 shares of company stock valued at $37,989,998 in the last 90 days. Corporate insiders own 20.50% of the company’s stock.

Medpace Trading Down 1.1%

MEDP opened at $590.30 on Wednesday. The company has a fifty day moving average price of $541.49 and a two-hundred day moving average price of $491.49. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a market cap of $16.48 billion, a P/E ratio of 34.60, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MEDP. BMO Capital Markets lifted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Finally, Mizuho boosted their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.